Global Fibromyalgia Syndrome Market, By Drug Class (Antidepressants, Anticonvulsants, Muscle Relaxants, Analgesics), Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Fibromyalgia Syndrome Market
Fibromyalgia syndrome market is expected to gain market growth at a potential rate of 6.25% in the forecast period of 2021 to 2028. Rise in the number of these diseases is the vital factor escalating the market growth.
Fibromyalgia disorder is characterized by musculoskeletal pain as well as characteristics of fatigue, sleep disorders, memory and mood issues, irritable bowel syndrome, headaches, depression, and anxiety. It is believed that fibromyalgia alters the pain sensations mechanism controlled by the brain
Increase in incidence of chronic diseases of the liver, heart, kidneys, pancreas, and blood disorders will uplift the market growth, also rise in the prevalence of the disease, rise in the healthcare affordability in the US and rise in the knowledge and awareness amongst the people are some of the crucial factors among others driving the fibromyalgia syndrome market growth. Moreover, rise in the personalized medicines for the treatment, rise in the research and development activities in the market and rise in the collaborations for product development will further create new opportunities for the fibromyalgia syndrome market in the forecast period of 2021-2028.
However, rise in the lack of patient awareness, side effects associated with drugs, and poor reimbursement in the market are the major factors among others acting as restraints, and will further challenge the fibromyalgia syndrome market in the forecast period mentioned above.
Fibromyalgia syndrome market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the fibromyalgia syndrome market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Fibromyalgia Syndrome Market Scope and Market Size
Fibromyalgia syndrome market is segmented on the basis of drug class and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug class, fibromyalgia syndrome market is segmented into antidepressants, anticonvulsants, muscle relaxants and analgesics.
Fibromyalgia syndrome market is also segmented on the basis of distribution channel into hospitals pharmacies, drug stores, retail pharmacies and online pharmacies.
Fibromyalgia Syndrome Market Country Level Analysis
Fibromyalgia syndrome market is analysed and market size information is provided by country, drug class and distribution channel as referenced above.
The countries covered in the fibromyalgia syndrome market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the fibromyalgia syndrome market due to rise in the prevalence of the disease, rise in the healthcare affordability in the US and rise in the knowledge and awareness amongst the people in this region. This region is also expected to witness substantial growth in the forecast period of 2021 to 2028.
The country section of the fibromyalgia syndrome market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Fibromyalgia syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Fibromyalgia Syndrome Market Share Analysis
Fibromyalgia syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to fibromyalgia syndrome market.
The major players covered in the fibromyalgia syndrome market report are Pfizer Inc., AstraZeneca, Eli Lilly and Company, Abiogen Pharma S.p.A., Merck Sharp & Dohme Corp., Novartis AG, GlaxoSmithKline plc., Zimmer Biomet, Johnson & Johnson Private Limited, Ampio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma Inc., BioDelivery Sciences International, Inc.., Crystal Genomics, Daiichi-Sankyo Company Limited, and Endo Pharmaceuticals Inc. among other domestic and global players. Fibromyalgia syndrome market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-